Suggested remit: To appraise the clinical and cost effectiveness of enfortumab vedotin with pembrolizumab within its marketing authorisation for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6607
Provisional Schedule
- Committee meeting:
- 07 October 2026
- Expected publication:
- 10 February 2027
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- MSD (pembrolizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action Bladder Cancer UK
- Black Health Agency for Equality
- Bladder and Bowel Community
- Bladder and Bowel UK
- Cancer 52
- Cancer Black Care
- Fight Bladder Cancer
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- British Association of Urological Nurses
- British Association of Urological Surgeons
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society of Urogenital Radiology
- British Society of Urogynaecology
- British Uro-Oncology Group
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Urology Foundation
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Astellas Pharma (enfortumab vedotin)
- Amarox (cisplatin)
- AstraZeneca (durvalumab)
- Bristol Myers Squibb (nivolumab)
- Hospira UK (cisplatin, gemcitabine)
- Sandoz (cisplatin)
- Sun Pharma (gemcitabine)
- Synchrony (gemcitabine)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning CommitteeScottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Urology
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 March 2026 | Invitation to participate |
| 23 January 2026 - 20 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6607 |
| 16 January 2026 | Note - Note added to the project documents |
| 07 November 2025 | In progress. Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early March 2026 when we will write to you about how you can get involved. |
| 07 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual